Basic science: (March 2008)

Abstract

1. Arendt LM, Schuler LA. Transgenic models to study actions of prolactin in mammary neoplasia. J Mammary Gland Biol Neoplasia 2008; 13: 29–40. 2. Bai T, Luoh SW. GRB-7 facilitates HER-2/ Neu-mediated signal transduction and tumor formation. Carcinogenesis 2008; 29: 473–479. 3. Boersma BJ, Reimers M, Yi M, Ludwig JA, Luke BT, Stephens RM, Yfantis HG, Lee DH, Weinstein JN, Ambs S. A stromal gene signature associated with inflammatory breast cancer. Int J Cancer 2008; 122: 1324–1332. 4. Camps C, Buffa FM, Colella S, Moore J, Sotiriou C, Sheldon H, Harris AL, Gleadle JM, Ragoussis J. hsa-miR-210 is induced by hypoxia and is an independent prognostic factor in breast cancer. Clin Cancer Res 2008; 14: 1340–1348. 5. Cha JY, Lambert QT, Reuther GW, Der CJ. Involvement of fibroblast growth factor receptor 2 isoform switching in mammary oncogenesis. Mol Cancer Res 2008; 6: 435–445. 6. Chanrion M, Negre V, Fontaine H, Salvetat N, Bibeau F, Mac Grogan G, Mauriac L, Katsaros D, Molina F, Theillet C, Darbon JM. A gene expression signature that can predict the recurrence of tamoxifen-treated primary breast cancer. Clin Cancer Res 2008; 14: 1744–1752. 7. Cheang MCU, Voduc D, Bajdik C, Leung S, McKinney S, Chia SK, Perou CM, Nielsen TO. Basal-like breast cancer defined by five biomarkers has superior prognostic value then triple-negative phenotype. Clin Cancer Res 2008; 14: 1368–1376. 8. Cortesio CL, Chan KT, Perrin BJ, Burton NO, Zhang S, Zhang ZY, Huttenlocher A. Calpain 2 and PTP1B function in a novel pathway with Src to regulate invadopodia dynamics and breast cancer cell invasion. J Cell Biol 2008; 180: 957–971. 9. Fitamant J, Guenebeaud C, Coissieux MM, Guix C, Trilleux I, Scoazec JY, Bachelot T, Bernet A, Mehlen P. Netrin-1 expression confers a selective advantage for tumor cell survival in metastatic breast cancer. Proc Natl Acad Sci USA 2008; 105: 4850–4855. 10. Fletcher O, Johnson N, Gibson L, Coupland B, Fraser A, Leonard A, Silva ID, Ashworth A, Houlston R, Peto J. Association of genetic variants at 8q24 with breast cancer risk. Cancer Epidemiol Biomarkers Prev 2008; 17: 702–705. 11. Fournier A, Fabre A, Mesrine S, Boutron-Ruault MC, Berrino F, Clavel-Chapelon F. Use of different postmenopausal hormone therapies and risk of histologyand hormone receptordefined invasive breast cancer. J Clin Oncol 2008; 26: 1260–1268. 12. Frank B, Wiestler M, Kropp S, Hemminki K, Spurdle AB, Sutter C, Wappenschmidt B, Chen XQ, Beesley J, Hopper JL, Meindl A, Kiechle M, Slanger T, Bugert P, Schmutzler RK, Bartram CR, Flesch-Janys D, Mutschelknauss E, Ashton K, Salazar R, Webb E, Hamann U, Brauch H, Justenhoven C, Ko YD, Bruning T, Silva IDS, Johnson N, Pharoah PPD, Dunning AM, Pooley KA, Chang-Claude J, Easton DF, Peto J, Houlston R, Chenevix-Trench G, Fletcher O, Burwinkel B. Association of a common AKAP9 variant with breast cancer risk: a collaborative analysis. J Natl Cancer Inst 2008; 100: 437–442. 13. Gold B, Kirchhoff T, Stefanov S, Lautenberger J, Viale A, Garber J, Friedman E, Narod S, Olshen AB, Gregersen P, Kosarin K, Olsh A, Bergeron J, Ellis NA, Klein RJ, Clark AG, Norton L, Dean M, Boyd J, Offit K. Genome-wide association study provides evidence for a breast cancer risk locus at 6q22-33. Proc Natl Acad Sci USA 2008; 105: 4340–4345. 14. Goodell V, Waisman J, Salazar LG, dela Rosa C, Link J, Coveler AL, Childs JS, Fintak PA, Higgins DM, Disis ML. Level of HER-2/neu protein expression in breast cancer may affect the development of endogenous HER-2/ neu-specific immunity. Mol Cancer Ther 2008; 7: 449–454. 15. Han HJ, Russo J, Kohwi Y, Kohwi-Shigematsu T. SATB1 reprogrammes gene expression to BCO/835/2008/JW